Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects
Ang-(1-7)
1 other identifier
interventional
32
0 countries
N/A
Brief Summary
In the modern concept of Renin-angiotensin System, Angiotensin-(1-7) plays a key role and demonstrates promising therapeutic potential due to it is generally opposite effects to Angiotensin II. The aim is to evaluate the effect of Ang-(1-7) acute administration on systolic and diastolic blood pressure (SBP and DBP) and heart rate (HR) in healthy and hypertensive subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for early_phase_1 hypertension
Started Jan 2014
Typical duration for early_phase_1 hypertension
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
December 2, 2016
CompletedFirst Posted
Study publicly available on registry
December 23, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedDecember 23, 2016
December 1, 2016
3.1 years
December 2, 2016
December 20, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Absence of adverse effects after Ang-(1-7) acute administration
Along 25 hours
Secondary Outcomes (4)
Blood Pressure Changes after Ang-(1-7) administration
Recording along 24 hours
Ang-(1-7) effects on Blood Pressure Variability
Along 1 hours after Ang-(1-7) acute administration
Heart Rate Changes after Ang-(1-7) administration
Recording along 24 hours
Ang-(1-7) effects on Heart Rate Variability
Along 1 hours after Ang-(1-7) acute administration
Study Arms (2)
Healthy Subjects
EXPERIMENTALPlacebo and Angiotensin-(1-7) acute infusion
Hypertensive Subjects
EXPERIMENTALPlacebo and Angiotensin-(1-7) acute infusion
Interventions
Eligibility Criteria
You may qualify if:
- arterial pressure \<140/90 mmHg
- body mass index (BMI) between 18,5 and 29 Kg/m2
- anti-hypertensive drug treatment
- ambulatory blood pressure monitoring (ABMP) \>130/85 mmHg
- body mass index between 18,5 and 29 Kg/m2
You may not qualify if:
- drug treatment
- recent surgeries
- pregnancy
- previous cardiovascular events
- high performance athletes
- dislipidemia
- diabetes
- renal injury
- obesity (BMI above 30 kg/m2)
- alcoholism
- smoking.
- recent surgeries
- pregnancy
- beta-blockers drug treatment
- previous cardiovascular events
- +7 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NON RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 2, 2016
First Posted
December 23, 2016
Study Start
January 1, 2014
Primary Completion
February 1, 2017
Study Completion
March 1, 2017
Last Updated
December 23, 2016
Record last verified: 2016-12